查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年排卵预测器的全球市场
市场调查报告书
商品编码
1153806

2022-2029 年排卵预测器的全球市场

Global Ovulation Predictors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

排卵是每个月从卵巢中释放一个卵子的生物学过程。排卵前，女性的身体通常在月经週期中期向血液中释放大量黄体生成素 (LH)。排卵预测试剂盒检测排卵前尿液中 LH 浓度的增加。这些测试预测排卵时间和生育高峰期。排卵前检测试剂盒根据尿液中的 LH 浓度、唾液中的电解质浓度或用户的基础体温来预测排卵。排卵预测因子可以在您自己舒适的家中进行测试，并有助于检测黄体生成素和另一种类似激素的物质雌激素。

市场动态

妊娠并发症的增加推动了市场、易用性和测试的可及性、妊娠管理和女性健康的改善、技术的进步以获得可靠和准确的结果。

预计排卵预测技术的进步将推动市场增长。

希望怀孕的女性越来越多地使用专为智能手机和类似设备设计的生育力追踪软件应用程序 (apps) 来计时性交。许多怀孕应用程序仅根据用户的数据进行预测，例如最近的月经日和月经週期。然而，事实证明，仅凭日历无法检测易孕期窗口或排卵期。一项研究发现，週期跟踪应用程序只有 21% 的机会正确识别女性的排卵日期。因此，人们认为结合排卵测试试剂盒的准确性和应用程序的易用性来确定可能的排卵日的方法将对希望怀孕的女性有用。例如，Clearblue Connected 排卵测试系统（Swiss Precision Diagnostics [SPD] GmbH，瑞士日内瓦）专供女性家庭使用。通过跟踪排卵前 LH 和 E3G 水平的升高，可以可靠地预测生育期。 21 测试系统可以通过蓝牙连接到用户的智能手机，软件记录女性的月经週期并使用该信息来确定何时进行尿液测试。尿液激素测试在三种程度之一进行：当激素水平处于基线时较低，当监测器检测到 E3G 水平升高时较高，当检测到 LH 激增时达到生育高峰。它反映了什么因此，上述因素有望在预测期内推动市场。

约束

排卵测试不能确认排卵，但可以确定排卵前的黄体生成素。如果您正在使用促排卵药物，排卵检测试剂盒将无法正常工作。 40 岁以上的女性或已经绝经的女性不能使用排卵试纸。对使用排卵检测试剂盒的认识不足以及使用这些设备的优势是预计在预测期内阻碍市场的因素。

COVID-19 影响分析

COVID-19 大流行是人类在上个世纪面临的最具破坏性的健康危机。缺乏可行的药物选择阻碍了与这种疾病的斗争。目前，尚无临床许可的疫苗或药物可用于治疗 COVID-19，并且对新疗法的不懈探索正以大流行的速度进行。此外，由于在家工作的文化，人们大部分时间都在家里并且不在工作。此外，在家工作已成为主流，让我从工作中解脱出来，让我可以与家人共度美好时光。这一时期受孕率上升，排卵试纸市场活跃。由于当地零售商开门营业，排卵试纸并不短缺，但由于排卵试纸产量低，排卵试纸市场的需求下降。在 COVID-19 之后，排卵测试市场有望快速增长。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 预计排卵预测技术的进步将推动市场增长。
    • 约束因素
      • 对使用排卵检测试剂盒的认识不足预计会阻碍市场增长。
    • 市场机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 尿液排卵测试试剂盒
    • 试纸法
    • 中游法
  • 唾液排卵测试
  • 唾液腺排卵测试试剂盒

最终用户第 8 章

  • 医院
  • 诊所
  • 诊断中心
  • 生育中心
  • 家庭护理
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第11章公司简介

  • Swiss Precision Diagnostics GmbH
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Church & Dwight Co. Inc.
  • Prestige Consumer Healthcare, Inc.
  • Hilin Life Products
  • Fairhaven Health LLC
  • Geratherm Medical AG
  • Piramal Enterprises Ltd.
  • Clearblue
  • Fertility Focus Limited
  • Accuquik

第12章 排卵预测器的全球市场-DataM

简介目录
Product Code: DMCD1075

Market Overview

The global ovulation predictors market size was valued around US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Ovulation is a biological process of releasing eggs from the ovary every month. Before ovulation, the female body releases luteinizing hormones (LH) in a large amount into the blood, which usually takes place in the middle of the menstrual cycle. Ovulation predictors detect a rise in LH in urine as its concentration increases before the ovulation phase. These tests predict ovulation time and peak fertility. Ovulation predictors are based on LH levels in urine, electrolyte levels in saliva, or the user's basal body temperature. Ovulation predictors provide the comfort of testing at home and help in the detection of luteinizing hormone along with another hormone-like, estrogen.

Market Dynamics

A rise in pregnancy complications drives the market, easy usage and availability of tests, increased pregnancy management and women's health, and technological advancements for reliable and accurate results.

Technological advancement in ovulation predictors is expected to drive market growth.

Fertility-tracking software applications (apps) designed for smartphones and similar devices are increasingly used to time intercourse by women seeking to conceive. Most fertility apps provide forecasts based entirely on user data, such as the latest menstrual period date and cycle duration. However, using a calendar alone to detect the viable window and ovulation has proved ineffective. One study discovered that by utilizing cycle-tracking apps, the probability of correctly identifying a woman's day of ovulation was only 21%. As a result, a way of determining the viable window that combines the precision of an ovulation test with the ease of an app could be useful to women trying to conceive. For instance, The Clearblue Connected Ovulation Test System (Swiss Precision Diagnostics [SPD] GmbH, Geneva, Switzerland) is intended for home use by women. It may reliably forecast the fertile window by tracking spikes in LH and E3G levels that precede ovulation. 21 The test system can link to the user's smartphone through Bluetooth, where the software records the woman's menstrual cycle and uses this information to determine when to perform the pee tests. The urine hormone test reflects one of three degrees of fertility: low when hormone levels are at baseline, high when the monitor detects increasing E3G levels, and peak fertility when the LH surge is detected. Thus, from the above factors, the market is expected to drive in the forecast period.

Restraint:

However, the ovulation test doesn't confirm ovulation; it simply identifies the Luteinizing hormone that precedes ovulation. If the User is on any fertility drugs, the ovulation test does not function properly. The ovulation test does not function for women over 40 or already approaching menopause. Low awareness regarding using Ovulation test kits and the benefits of using devices are the factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic is the most devastating health crisis that humanity has faced in the last century. The lack of viable medicinal options has hampered the fight against the disease. There is currently no clinically licensed vaccine or medicine to treat COVID-19, and the continuous hunt for a novel cure is moving at a pandemic pace. Moreover, because of the work-from-home culture, people mainly stayed at home and had an extended break from work. The respite from their hectic schedules allowed them to spend quality time with their families. Pregnancy rates increased during this time, which boosted the ovulation test kit market. There was no shortage of ovulation test kits because local retailers were open; nonetheless, the low output of ovulation test kits reduced demand in the ovulation test market. Following the post-COVID-19 situation, the ovulation kit test market will likely grow rapidly.

Segment Analysis

Urine-Based Ovulation Test Kit segment is estimated to hold the largest market share in ovulation predictors market.

The urine-based ovulation test kit segment accounted for the largest market share in 2021. The segment benefits because these are more accurate than salivary ferning kits, but they're not foolproof. These are very easy to use and can be bought bulk from any supermarket. Urine-Based Test Ovulation Test Kit comes with test strips or sticks. For instance, Clearblue Easy Fertility Monitor, this monitor detects two hormones, LH and estrogen. It allows for detection on more fertile days than paper tests. Therefore, it has increased the demand for the urine-based ovulation test kit. Thus, from the above factors, the market segment is accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ovulation predictors market

North America accounted for the largest market share in 2021. Technological advancements in the ovulation predictors, higher adoption of the tests, partnerships and collaborations by the key market players in the region are the factors to drive the market in the forecast period. For instance, a team of Brigham researchers has created a low-cost smartphone gadget that can predict ovulation and aid in family planning using the latest technological advancement. The instrument automatically recognizes fern-like patterns-a hallmark of ovulation-in a saliva sample using microfluidic technology (in which fluids flow through small channels), artificial intelligence (AI), and the pervasiveness of smartphones. The scientists tested the device's effectiveness in the lab using artificial saliva. They validated the results with saliva samples from six patients, achieving higher than 99 percent accuracy in predicting ovulation.

Additionally, through the Real Talk with Conceiving Hood Campaign, actress Jordana Brewster collaborated with Clearblue in April 2021 to raise awareness about the difficulty in conceiving and fertility in women. Therefore, it has increased the adoption of ovulation predictors in the region. Thus, from the above factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the ovulation predictors market are: Swiss Precision Diagnostics GmbH, Hilin Life Products, Fairhaven Health LLC, Geratherm Medical AG, Church & Dwight Co. Inc., Prestige Consumer Healthcare, Inc., Piramal Enterprises Ltd., Clearblue, Fertility Focus Limited, and Accuquik.

Swiss Precision Diagnostics GmbH:

Overview:

Swiss Precision Diagnostics (SPD) was formed as a joint venture between Procter & Gamble (P&G) and Alere (now a part of the Abbott group, since October 2017) to create, using its parent companies complementary strengths, one of the world's foremost organizations in consumer diagnostics. Alere (a wholly owned subsidiary of Abbott) is among the world's leading providers of innovative diagnostic products, renowned for their proven reliability in the professional management of women's health and chronic and infectious disease. SPD is currently a leading home pregnancy and fertility/ovulation test supplier. The company has a strong focus on women's reproductive health, and its goals are in the continuing supply of diagnostic products which are accurate, simple and affordable.

Product Portfolio:

Clearblue Advanced Fertility Monitor: Clearblue Advanced Fertility Monitor is one of the most advanced home method proven to increase a woman's chance of conceiving by up to more than 85% in the first two cycles of use. The monitor reliably identifies the days of the cycle when women are most likely to conceive - these are the days before the day of ovulation when an egg is released from the ovary. Having sexual intercourse on the day of ovulation and the days leading up to ovulation provides the best chances of conceiving. The product consists of a handheld monitor and disposable test sticks. The monitor tells the woman when to test and indicates her level of fertility each day. Two hormones are monitored - estrone-3-glucuronide (E3G), a urinary metabolite of estrogen and luteinizing hormone (LH). By monitoring both hormones, the monitor can identify more fertile days than any other home method. It is a unique innovation for couples who are proactively planning pregnancy. It is simple to use, completely natural and 99% accurate in detecting the LH surge.

The global ovulation predictors market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in ovulation predictors is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Low awareness regarding using Ovulation test kits is expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Urine-Based Ovulation Test Kit*
      • 7.2.1.1. Test Strip Method
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Mid-Stream Method
  • 7.3. Saliva-Based Ovulation Test Kit
  • 7.4. Salivary Ferning Ovulation Test Kits

8. By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Diagnostic Centers
  • 8.5. Fertility Centers
  • 8.6. Homecare
  • 8.7. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Swiss Precision Diagnostics GmbH*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Church & Dwight Co. Inc.
  • 11.3. Prestige Consumer Healthcare, Inc.
  • 11.4. Hilin Life Products
  • 11.5. Fairhaven Health LLC
  • 11.6. Geratherm Medical AG
  • 11.7. Piramal Enterprises Ltd.
  • 11.8. Clearblue
  • 11.9. Fertility Focus Limited
  • 11.10. Accuquik

LIST NOT EXHAUSTIVE

12. Global Ovulation Predictors Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Applications
  • 12.3. Contact Us